Clinical trial NCT03787238: A Randomized, Multicenter, Study for the prEvention and Acute Treatment of Migraine (REAL)
Official title: GM-18 - A Randomized, Multicenter, Study for the prEvention and Acute Treatment of Migraine Using Open Label Non-invasive Vagal Nerve Stimulation, Versus Standard of Care (REAL)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Migraine
Lead sponsor: ElectroCore INC
Sponsor class: INDUSTRY
First posted: 2018-12-26
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is a randomized study for the prevention and acute treatment of migraine using open label nVNS and standard of care versus standard of care.

.

Detailed description: A randomized study for the prevention and acute treatment of migraine using open label nVNS and standard of care versus standard of care.

Eligible subjects will participate in a 4 week run-in period after which they will be randomized (1:1) to either nVNS and standard of care (nVNS group) or standard of care (SOC group) for 12 weeks. The nVNS group will use the nVNS device preventatively and acutely for the treatment of migraine. The SOC group will continue to use their regular standard of care migraine treatment medications for the duration of the 12 week randomized period.

Eligibility criteria: Inclusion Criteria:

* Is 18 years of age or above.
* Has been previously diagnosed with episodic or chronic migraine (with or without aura) in accordance with the ICHD-3 Classification criteria.
* Experience at least 6 and no more than 24 headache days per month and a minimum of 4 migraine attacks per month (over the last 3 months).
* Has age of onset of migraine less than 50 years old.
* Stable regime for any migraine preventative medications for the last 3 months and agrees to maintain stable regime for duration of the study.
* Agrees to and in clinician opinion is able to use the nVNS device as intended, follow all of the requirements of the study including follow-up visit requirements, record required study data in the subject dairy, and other self-assessment questionnaires.
* Availability of internet/Web access for Web-based e-diary completion
* Is able to provide written Informed Consent.

Exclusion Criteria:

* Requires use of oral or injectable steroids for concomitant medical condition that in the opinion of the investigator will interfere with the study.
* Has a history of any intracranial aneurysm, intracranial haemorrhage, brain tumour or significant head trauma.
* Has a structural abnormality at the nVNS treatment site (e.g. lymphadenopathy previous surgery or abnormal anatomy).
* Has pain at the nVNS treatment site (e.g. dysesthesia, neuralgia and/or cervicalgia).
* Has other significant pain problem (e.g. cancer pain or other head or facial disorder) that in the opinion of the investigator may confound the study assessments
* Has known or suspected severe cardiac disease (e.g. symptomatic coronay artery disease, prior myocardial infarction, congestive heart failure (CHF)).
* Has known or suspected severe cerebrovascular disease, (e.g. prior stroke or transient ischemic attack, symptomatic carotid artery disease, prior cartoid endarterectomy or other vascular neck surgery).
* Has known or suspected own and/or family history of cardiac disease (including but not limited to ischemic heart disease, rhythm disturbances, congenital abnormalities cardiac myopathies), or presents risk factors strongly associated with risk for developing cardiologic abnormalities that in the opinion of the investigator might compromise subjects safety using n-VNS.
* Has had a cervical vagotomy.
* Has uncontrolled high blood pressure (systolic \>160 diastolic \> 100 after 3 repeated measurements within 24 hours).
* Is currently implanted with an electrical and/or neurostimulator device (e.g. cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, cochlear implant, Spehnopalatine ganglion stimulator or Occiptial nerve stimulator).
* Has been implanted with metal cervical spine hardware or has a metallic implant near the nVNS stimulation site (e.g. in the head, neck of thorax).
* Presents a suspicion of secondary headache.
* Previous diagnosis of medication overuse headache within the last 3 months
* Has a history of syncope (within the last 1 year).
* Has a history of seizures (within the last 1 year).
* Has a known or suspicion of substance abuse or addiction (within the last 1 year).
* Has initiated medications for migraine prophylaxis in the previous 30 days, or in the case of Botulinum toxin and monoclonal antibodies against CGRP injections in the previous 90 days.
* Has failed an adequate trial (two months or greater) of at least 3 classes of a drug therapy for the prophylaxis of migraine.
* Is pregnant or of childbearing years and is unwilling to use and accepted form of birth control (condom or contraceptive pill).
* Is participating in any other therapeutic clinical investigation or has participated in a clinical trial in the preceding 30 days.
* Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with the follow-up requirements, or provide self- assessments is compromised (e.g. homeless, developmentally disabled and prisoner).
* Has previously used the gammaCore device within the last 3 months.

Primary outcomes:
measure: Reduction in number of migraine days during the last four weeks in the twelve-week randomized period compared with the four-week run-in period
timeFrame: The last four weeks in the randomization period compared to the four week run-in period.
Secondary outcomes:
measure: Reduction in number of headache days during the last four-weeks in the twelve-week randomized period compared to the four-week run-in period
timeFrame: The last four weeks in the randomization period compared to the four week run-in period.
measure: Reduction in number of migraine days and headache days (separately)
timeFrame: 12 week randomised period
measure: Rate of responders for the nVNS group compared to the standard of care group.
timeFrame: The last four weeks in the randomization period compared to the four week run-in period.
measure: Acute treatment response for nVNS and standard of care therapies
timeFrame: 12 week randomised period
measure: Consistency of response
timeFrame: 12 week randomised period
measure: Safety and tolerability of nVNS as measured by adverse events
timeFrame: 12 week randomised period
Other outcomes:
measure: Change in acute headache medication use
timeFrame: 12 week randomization period compared to the four week run-in period
measure: Presence or absence of nausea, vomiting, photophobia, phonophobia
timeFrame: 12 week randomised period
Locations:
city: Glostrup
country: Denmark
facility: Danish Headache Center
city: Hamburg
country: Germany
facility: CTC, University Medical Center Hamburg-Eppendorf
city: Königstein im Taunus
country: Germany
facility: Migräne- und Kopfschmerzklinik Königstein
city: München
country: Germany
facility: Klinik für Neurologie, Ludwig-Maximilliams-Universität, Klinikum Grosshadern
city: Rostock
country: Germany
facility: Klinik und Poliklinik für Neurologie, Universitätsmedizin Rostock
city: Mondino
country: Italy
facility: National Neurological Institute C. Mondino Foundatio
state: Pavia
city: Milan
country: Italy
facility: U.O. Neurologia III - Cefalee e Neuroalgologia, Fondazione IRCCS Istituto
city: Rome
country: Italy
facility: Department of Neurological, Motor and Sensorial Sciences, IRCCS San Raffaele
city: Turin
country: Italy
facility: University of Turin
city: Barcelona
country: Spain
facility: Headache Unit, University Hospital Vall d'Hebron
city: Madrid
country: Spain
facility: Servicio de Neurologia, Hospital Ruber Internacional
city: Pamplona
country: Spain
facility: Servicio de Neurologia, Clinica Universidad de Navarra
city: Valencia
country: Spain
facility: Servicio de Neurologia, Hospital Clinico Universitario de Valencia
city: Hull
country: United Kingdom
facility: Hull Royal Infirmary, Neurology Department
state: East Yorkshire
city: Birmingham
country: United Kingdom
facility: University of Birmingham
city: Gateshead
country: United Kingdom
facility: Queen Elizabeth Hospital Queen
city: Sunderland
country: United Kingdom
facility: Sunderland Royal Hospital
Study officials:
affiliation: University of Birmingham
name: Alexandra Sinclair, MD
role: PRINCIPAL_INVESTIGATOR
References: